美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Prospect Capital Corp

25.06

0.0000

成交量：- -

成交額：31.97萬

市值：92.18億

市盈率：68.17

高：25.06

開：25.06

低：25.06

收：25.06

52周最高：26.49

52周最低：25.00

股本：3.68億

流通股本：- -

量比：- -

換手率：- -

股息：0.72

股息率：2.87%

每股收益(TTM):0.3676

每股收益(LYR):0.3948

淨資產收益率：4.16%

總資產收益率：4.83%

市淨率：2.90

市盈率(LYR):63.48

資料載入中...

總覽公司新聞資訊公告

Tharimmune, Inc.盤中異動早盤急速拉升5.14%報4.50美元

原發性膽汁性膽管炎新藥在海南博鰲樂城獲批

吉利德：原發性膽汁性膽管炎藥物Seladelpar在海南博鰲樂城獲批

Tharimmune, Inc.盤中異動早盤股價大漲9.48%報2.54美元

Tharimmune, Inc.盤中異動臨近午盤股價大跌6.46%

創新診療技術集中展示，心血管、眼科、感染等多個疾病領域在第八屆進博會迎來診療新進展

吉利德「進博會」達成多項合作推動健康公平可及

中国网财经

全球知名藥械龍頭集體攜創新成果亮相進博會

广州日报新花城

（第八屆進博會）跨國藥企深耕進博會加速創新成果落地

中国新闻网

進博觀察：開放平台引「鳳」來，醫療藥械煥新健康動能

21世纪经济报道

吉利德四赴進博會：全球首款長效HIV預防藥亞洲首秀

南方都市报

啱啱！利好突襲直線爆拉！

中国基金报

OpenAI CEO：將直播討論新企業結構及其他重要內容

跨國藥企高層：進博會強大「溢出效應」成全球創新成果落地「加速器」

中国新闻网

吉利德13款新藥加速惠及中國患者

Tharimmune, Inc.盤中異動股價大跌5.38%

Tharimmune, Inc.盤中異動股價大漲5.04%

原研藥退市連鎖反應：仿製藥遭「團滅」

上市公司花了1.25億元研發的仿製藥，上市申請被否！仿製對象已「翻車」：因安全性問題在歐美市場退市

每日经济新闻

Tharimmune, Inc.盤中異動早盤急速拉升5.38%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PBC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","market":"US","secType":"STK","nameCN":"Prospect Capital Corp","latestPrice":25.06,"timestamp":1640811600000,"preClose":25.06,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":367817926,"eps":0.367626,"marketStatus":"退市","change":0,"latestTime":"12-29 16:00:00 EST","open":25.06,"high":25.06,"low":25.06,"amount":319705.1613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.367626,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":25.06,"dividendRate":0.028731,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","floatShares":0,"roa":"4.83%","roe":"4.16%","lyrEps":0.394789,"shares":367817926,"dividePrice":0.72,"high":25.06,"amplitude":0,"preClose":25.06,"low":25.06,"week52Low":25,"pbRate":"2.90","week52High":26.49,"institutionHeld":0,"latestPrice":25.06,"eps":0.367626,"divideRate":0.028731,"volume":0,"delay":0,"ttmEps":0.367626,"open":25.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBC\",params:#limit:5,,,undefined,":[{"date":"2026-02-09","symbol":"PBC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770670800000,"name":null,"time":"盤後","dateTimestamp":1770613200000,"actualEps":null},{"date":"2025-08-26","symbol":"PBC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756238400000,"name":null,"time":"盤後","dateTimestamp":1756180800000,"actualEps":null},{"market":"US","date":"2021-12-30","symbol":"PBC","reason":null,"defaultRemindTime":1640874600000,"announcedDate":"2021-12-01","type":"delisting","dateTimestamp":1640840400000},{"market":"US","date":"2021-11-30","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1638282600000,"name":"Prospect Capital Corp","recordDate":"2021-12-15","payableDate":"2021-12-01","currency":"USD","type":"dividend","dateTimestamp":1638248400000},{"market":"US","date":"2021-08-31","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1630416600000,"name":"Prospect Capital Corp","recordDate":"2021-09-15","payableDate":"2021-09-01","currency":"USD","type":"dividend","dateTimestamp":1630382400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBC\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":"2019-03-01","paymentDate":"2019-03-15","value":0.4774306,"currency":"USD"},{"executeDate":"2019-08-29","recordDate":"2019-08-30","paymentDate":"2019-09-15","value":0.4296875,"currency":"USD"},{"executeDate":"2019-11-27","recordDate":"2019-11-29","paymentDate":"2019-12-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":"2020-03-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-05-29","recordDate":"2020-06-01","paymentDate":"2020-06-15","value":0.4296875,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611116168","title":"Tharimmune, Inc.盤中異動 早盤急速拉升5.14%報4.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611116168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611116168?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 00:15","pubTimestamp":1770999328,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日00时15分，Tharimmune, Inc.股票出现波动，股价快速上涨5.14%。截至发稿，该股报4.50美元/股，成交量11.1782万股，换手率0.28%，振幅6.54%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为2.04%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021400152897a62334&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021400152897a62334&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","CNTN","BK4139","THAR"],"gpt_icon":0},{"id":"2593424175","title":"原發性膽汁性膽管炎新藥在海南博鰲樂城獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593424175","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593424175?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 14:53","pubTimestamp":1766559180,"startTime":"0","endTime":"0","summary":"新京报讯 12月22日，原发性胆汁性胆管炎药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批，适用于与熊去氧胆酸联合治疗对UDCA单药应答不佳的PBC成人患者，或作为单药用于治疗无法耐受UDCA的PBC成人患者。该药也是全球首个获批用于治疗原发性胆汁性胆管炎的强效选择性过氧化物酶体增殖物激活受体δ激动剂。原发性胆汁性胆管炎已被纳入我国第二批罕见病目录。谢青表示，Seladelpar以其独特的作用机制为原发性胆汁性胆管炎的治疗带来了突破性变革。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512241356572843238.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512241356572843238.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1766559238168453.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1766559238168453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["PBC"],"gpt_icon":0},{"id":"2593246855","title":"吉利德：原發性膽汁性膽管炎藥物Seladelpar在海南博鰲樂城獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593246855","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593246855?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 10:45","pubTimestamp":1766457935,"startTime":"0","endTime":"0","summary":"【吉利德：原发性胆汁性胆管炎药物Seladelpar在海南博鳌乐城获批】12月22日，吉利德原发性胆汁性胆管炎(PBC)药物Seladelpar在海南博鳌乐城国际医疗旅游先行区获批，适用于与熊去氧胆酸（UDCA）联合治疗对UDCA单药应答不佳的PBC成人患者，或作为单药用于治疗无法耐受UDCA的PBC成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202512233599290123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBC"],"gpt_icon":0},{"id":"2593430618","title":"Tharimmune, Inc.盤中異動 早盤股價大漲9.48%報2.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593430618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593430618?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 22:31","pubTimestamp":1766413907,"startTime":"0","endTime":"0","summary":"北京时间2025年12月22日22时31分，Tharimmune, Inc.股票出现波动，股价快速拉升9.48%。截至发稿，该股报2.54美元/股，成交量21.4924万股，换手率0.61%，振幅2.15%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223147a46ae19c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222223147a46ae19c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","THAR","PBC"],"gpt_icon":0},{"id":"2582373562","title":"Tharimmune, Inc.盤中異動 臨近午盤股價大跌6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373562?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 00:30","pubTimestamp":1762878642,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日00时30分，Tharimmune, Inc.股票出现异动，股价快速下挫6.46%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为1.24%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112003042a49a46ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112003042a49a46ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","THAR","PBC"],"gpt_icon":0},{"id":"2582826343","title":"創新診療技術集中展示，心血管、眼科、感染等多個疾病領域在第八屆進博會迎來診療新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2582826343","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582826343?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 16:59","pubTimestamp":1762765157,"startTime":"0","endTime":"0","summary":"11月8日，吉利德与博鳌乐城国际医疗旅游先行区管理局、乐城医药监管局及多方代表共同庆祝全球同类首创、一年仅需给药两次的长效HIV暴露前预防药物Lenacapavir在博鳌乐城的正式落地和首例HIV暴露前预防应用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1762764680016280570","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PBC"],"gpt_icon":0},{"id":"2582624908","title":"吉利德「進博會」達成多項合作 推動健康公平可及","url":"https://stock-news.laohu8.com/highlight/detail?id=2582624908","media":"中国网财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582624908?lang=zh_tw&edition=fundamental","pubTime":"2025-11-08 18:52","pubTimestamp":1762599120,"startTime":"0","endTime":"0","summary":"中国网财经11月8日讯 第八届进博会期间，吉利德科学签署多项战略合作协议。吉利德科学全球副总裁、中国区总经理金方千表示，进入中国八年多来，吉利德始终以患者为中心，推动全球创新疗法快速惠及中国患者。截至目前，在中国正式获批的13款创新药物已累计惠及约180万患者。“依托进博会这一开放平台，我们持续拓展合作网络，推动扩大创新药物可及，提升患者的治疗体验和生活质量。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110819201294f79163&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110819201294f79163&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC"],"gpt_icon":0},{"id":"2581977080","title":"全球知名藥械龍頭集體攜創新成果亮相進博會","url":"https://stock-news.laohu8.com/highlight/detail?id=2581977080","media":"广州日报新花城","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581977080?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 01:13","pubTimestamp":1762362832,"startTime":"0","endTime":"0","summary":"进博会的“虹吸效应”与“溢出效应”吸引着全球知名药械龙头持续参会且表示出对中国创新药械发展越来越大的信心。本届进博会上，又是一次“百花齐放”。从“8”到“∞”，礼来携重磅创新成果赴约医药企业礼来今年以“礼创新程，无限未来”为主题参展，展台设计以数字“8”为灵感，象征无限可能与持续创新，彰显其对中国医疗健康事业的长期承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511063556200363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154245673.USD","BK4195","LU0154245756.USD","BK4229","PBC","RDN"],"gpt_icon":0},{"id":"2581777998","title":"（第八屆進博會）跨國藥企深耕進博會 加速創新成果落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777998","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581777998?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 22:40","pubTimestamp":1762353653,"startTime":"0","endTime":"0","summary":"中新社上海11月5日电(记者陈静)“过去七年，从展品到商品，再到临床广泛可及，进博会已成为创新药物加速惠及中国患者的重要催化平台。”诺华公司中国区副总裁，心血管、肾脏及代谢治疗领域兼创新患者服务负责人管宏5日对记者表示，得益于进博会的溢出效应，诺华公司多款心肾领域的创新药物实现首秀到落地的跨越。第八届中国国际进口博览会5日开幕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053556163538.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053556163538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4550","LU1585245621.USD","LU1674673428.USD","BK1161","LU0289739699.SGD","LU1778281490.HKD","SG9999015952.SGD","BK4566","LU0823416689.USD","LU1571399168.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","BK4532","LU1839511570.USD","BK4585","06978","BK4583","IE0002270589.USD","LU0114720955.EUR","LU1066051498.USD","LU0320765992.SGD","LU1430594728.SGD","BK4139","SG9999015986.USD","LU1674673691.USD","LU0058720904.USD","LU0234570918.USD","LU1066053197.SGD","BK4588","IE00BZ1G4Q59.USD","PBC","IE00B7SZLL34.SGD","SG9999015978.USD","LU2324357040.USD","LU0109394709.USD","LU0882574055.USD","GILD","LU2087621335.USD","BK1574","LU0889565916.HKD","IE00B3T34201.USD","BK4578","SG9999015945.SGD","LU2089984988.USD","BK4568","IE00BSNM7G36.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2581720929","title":"進博觀察：開放平台引「鳳」來，醫療藥械煥新健康動能","url":"https://stock-news.laohu8.com/highlight/detail?id=2581720929","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581720929?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 20:31","pubTimestamp":1762345866,"startTime":"0","endTime":"0","summary":"11月5日，第八届中国国际进口博览会（下称“进博会”）在上海盛大开幕。本届进博会吸引155个国家、地区和国际组织赴约，4108家境外企业带来最新成果，43万平方米展馆汇聚全球智慧，进博规模再创新高。自2018年首届以来，进博会已逐步强化国际采购、投资促进、人文交流、开放合作“四大平台”功能，成为全球瞩目的开放合作盛会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053556078911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053556078911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBC"],"gpt_icon":0},{"id":"2581715385","title":"吉利德四赴進博會：全球首款長效HIV預防藥亞洲首秀","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715385","media":"南方都市报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581715385?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 13:24","pubTimestamp":1762233852,"startTime":"0","endTime":"0","summary":"从“展品”到“药品”，从“首展”到“首用”，吉利德科学借进博会“黄金跑道”持续跑出“中国速度”。11月展台现场，吉利德将首次在亚洲公开展示这一全新的HIV预防方案，并同步披露其在全球同步研发框架下中国参与项目的最新进展——10项肿瘤、6项非肿瘤研究中，90%的肿瘤项目已实现与全球“零时差”开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104132704a6df8bb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104132704a6df8bb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4550","LU1778281490.HKD","SG9999015978.USD","LU0320765992.SGD","BK4566","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","PBC","IE00BSNM7G36.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU2087621335.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1674673691.USD","LU0058720904.USD","BK4578","LU0234570918.USD","LU2324357040.USD","BK4583","LU1430594728.SGD","LU0889565916.HKD","GILD","LU0114720955.EUR","LU1674673428.USD","SG9999015952.SGD","LU1585245621.USD","LU2089984988.USD","SG9999015945.SGD","LU1066051498.USD","LU1839511570.USD","BK4568","LU1571399168.USD","LU0289739699.SGD","SG9999015986.USD","LU1066053197.SGD","BK4532","LU0882574055.USD","IE0002270589.USD","BK4585","LU0823416689.USD","LU2468319806.SGD","BK4588"],"gpt_icon":0},{"id":"2579996194","title":"啱啱！利好突襲 直線爆拉！","url":"https://stock-news.laohu8.com/highlight/detail?id=2579996194","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579996194?lang=zh_tw&edition=fundamental","pubTime":"2025-10-28 23:39","pubTimestamp":1761665940,"startTime":"0","endTime":"0","summary":"OpenAI宣布已完成资本重组，确立其组织架构为：由非营利机构对其营利性业务持有控股权。这家人工智能初创公司表示，其非营利机构现更名为OpenAI基金会，并持有营利性部门约1300亿美元的股权。OpenAI称，其营利性部门现为一家公益性公司，名为OpenAI Group PBC。受消息影响，微软股价在盘前一度直线拉升，暴涨超5%；正式开盘之后，涨幅有所回落，总市值再度站上4万亿美元大关。收入分成协议将持续至独立专家小组核验AGI，但付款周期将拉长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510282348359746f3ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510282348359746f3ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1564329461.SGD","IE00B19Z8X17.USD","LU0390134368.USD","SG9999018857.SGD","LU2360108059.USD","IP","LU2023251221.USD","LU0708994859.HKD","IE00B3S45H60.SGD","LU2191332357.HKD","LU2023250504.SGD","LU2506951875.HKD","LU1674673691.USD","LU0234570918.USD","LU2420271590.USD","LU0353189763.USD","LU2506952170.USD","LU1481600234.SGD","LU2463028550.USD","PBC","LU2756315318.SGD","LU2360106780.USD","LU2860962120.EUR","IE00B4JS1V06.HKD","LU0011850046.USD","BK4532","IE00B7KXQ091.USD","IE00BJTD4N35.SGD","LU1674673428.USD","LU1989764664.SGD","LU2286300806.USD","LU1935043023.USD","BK4504","LU2756315664.SGD","SG9999014880.SGD","SG9999014575.USD","AGI","LU0640476718.USD","LU2456880835.USD","LU0316494557.USD","LU0889566641.SGD","LU1989764748.USD","MSFT","SG9999014914.USD","LU1935043536.SGD","LU0661504455.SGD","LU1815336760.USD","LU2506952097.USD","LU1564329115.USD","LU0426417589.USD"],"gpt_icon":1},{"id":"2578966616","title":"OpenAI CEO：將直播討論新企業結構及其他重要內容","url":"https://stock-news.laohu8.com/highlight/detail?id=2578966616","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578966616?lang=zh_tw&edition=fundamental","pubTime":"2025-10-28 22:54","pubTimestamp":1761663261,"startTime":"0","endTime":"0","summary":"<div class=\"text-18 font-400 tracking-1 leading-40 line-clamp-4 whitespace-pre-line text-custom-000000/70 dark:text-custom-FFFFFF/60 [&amp;_span]:!text-custom-000000/70 [&amp;_span]:dark:!text-custom-FFFFFF/60 [&amp;_span]:!bg-transparent [&amp;_a]:!text-custom-55942D [&amp;_a]:dark:!text-custom-55942D\"><p>Odaily星球日报讯 OpenAI CEO Altman 在社交媒体平台“X”上表示，将于（太平洋时间）今天上午 10:30（北京时间次日凌晨 1:30）进行一次直播，回答问题。直播会谈到新企业结构，但也会讨论我们新的研究目标、产品演进、基础设施建设的最新进展、非营利组织的初步资金领域等等。这可能是我们今年要说的最重要的内容。非营利组织仍然掌控一切，如果我们做好了工作，它将成为资源最丰富的非营利组织。我们很高兴立即开始部署资本。我们的有限责任公司（LLC）将转变为公共利益公司（PBC）。(金十)</p></div>","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/zh-CN/newsflash/454346","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["PBC"],"gpt_icon":0},{"id":"2577307068","title":"跨國藥企高層：進博會強大「溢出效應」成全球創新成果落地「加速器」","url":"https://stock-news.laohu8.com/highlight/detail?id=2577307068","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577307068?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 21:06","pubTimestamp":1761224803,"startTime":"0","endTime":"0","summary":"中新网上海10月23日电(记者陈静)“进博会已成为全球新品首发、技术首秀和共享中国机遇的重要平台。过去连续三年参展，我们深切感受到进博会的‘溢出效应’，多款创新疗法通过‘进博快车’加速落地，更快惠及中国患者。”吉利德科学全球副总裁、中国区总经理金方千23日对记者表示。第八届中国国际进口博览会(简称：进博会)将要开幕，全球领先的生物制药企业吉利德科学将第四次亮相进博会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510233542559744.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510233542559744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","IE00B19Z3581.USD","LU1066053197.SGD","LU0889565916.HKD","LU0289739699.SGD","LU2324357040.USD","IE0002270589.USD","LU0823416689.USD","BK4139","IE00BZ1G4Q59.USD","LU0109394709.USD","BK4583","SG9999015978.USD","LU1430594728.SGD","LU2087621335.USD","IE00BKVL7J92.USD","LU0320765992.SGD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU1585245621.USD","LU1839511570.USD","BK4585","IE00B3T34201.USD","LU2468319806.SGD","LU0114720955.EUR","BK4588","LU0882574055.USD","LU2089984988.USD","SG9999015986.USD","BK4550","LU0058720904.USD","PBC","LU1674673428.USD","BK4566","IE00B7SZLL34.SGD","GILD","LU0234570918.USD","SG9999015952.SGD","BK4578","LU1674673691.USD","SG9999015945.SGD","IE00BSNM7G36.USD","LU1066051498.USD","BK4568","LU1571399168.USD"],"gpt_icon":0},{"id":"2577306333","title":"吉利德13款新藥加速惠及中國患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2577306333","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577306333?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 19:16","pubTimestamp":1761218177,"startTime":"0","endTime":"0","summary":"第八届中国国际进口博览会将于11月5日在上海开幕，吉利德科学将第四次亮相这一盛会。吉利德科学全球副总裁、中国区总经理金方千表示：“进博会已成为全球新品首发、技术首秀和共享中国机遇的重要平台。过去连续三年参展，我们深切感受到进博会的溢出效应，多款创新疗法通过‘进博快车’加速落地，更快惠及中国患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510233542486544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","PBC","BK1574","BK1161"],"gpt_icon":0},{"id":"2577387943","title":"Tharimmune, Inc.盤中異動 股價大跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577387943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577387943?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 21:59","pubTimestamp":1761055143,"startTime":"0","endTime":"0","summary":"北京时间2025年10月21日21时59分，Tharimmune, Inc.股票出现异动，股价快速下挫5.38%。Tharimmune, Inc.股票所在的生物技术行业中，整体跌幅为0.75%。其相关个股中，Minerva Neurosciences, Inc、Cero Therapeutics Holdings Inc C/Wts 14/02/2029 、Ibio, Inc.涨幅较大，Minerva Neurosciences, Inc、Ibio, Inc.、Rani Therapeutics Holdings, Inc.较为活跃，换手率分别为1205.30%、166.31%、49.04%，振幅较大的相关个股有Minerva Neurosciences, Inc、Cero Therapeutics Holdings Inc C/Wts 14/02/2029 、Ibio, Inc.，振幅分别为215.34%、78.99%、47.03%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102121590394d5f53d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102121590394d5f53d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","BK4139","THAR"],"gpt_icon":0},{"id":"2575477592","title":"Tharimmune, Inc.盤中異動 股價大漲5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575477592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575477592?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 01:04","pubTimestamp":1760461453,"startTime":"0","endTime":"0","summary":"北京时间2025年10月15日01时04分，Tharimmune, Inc.股票出现异动，股价大幅上涨5.04%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。其相关个股中，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Senti Biosciences, Inc.涨幅较大，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为2802.30%、38.15%、37.55%，振幅较大的相关个股有Pmgc Holdings Inc.、Cdt Equity Inc C/Wts 22/09/2028、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com，振幅分别为55.85%、38.33%、37.50%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501041394c91e45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501041394c91e45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","PBC","BK4139"],"gpt_icon":0},{"id":"2575290118","title":"原研藥退市連鎖反應：仿製藥遭「團滅」","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290118","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290118?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 19:29","pubTimestamp":1760441340,"startTime":"0","endTime":"0","summary":"10月11日，NMPA下发了43条不带药品批号的“通知件”，其中包括复旦张江的奥贝胆酸片。复旦张江奥贝胆酸片的进口原研药因安全性问题在海外“翻车”，遭欧美市场退市，是此次监管机构不予批准的主要原因。国产仿制药被波及随着原研药安全性风险的暴露以及在欧美市场接连退市，其在国内的仿制前景也面临极大的不确定性。截至目前，国内尚无奥贝胆酸上市。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-10-14/doc-inftwhpf1932544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","FXR","PBC","BK4585","CMA","BK4207","BK4081","BK4211","EMA","BK4589"],"gpt_icon":0},{"id":"2575025050","title":"上市公司花了1.25億元研發的仿製藥，上市申請被否！仿製對象已「翻車」：因安全性問題在歐美市場退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575025050","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575025050?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 12:55","pubTimestamp":1760417700,"startTime":"0","endTime":"0","summary":"仿制对象已“翻车”：因安全性问题在欧美市场退市，所有相关临床试验被暂停。　　10月13上市公司花了1.25亿元研发的仿制药，上市申请被否！　　复旦张江奥贝胆酸片的进口原研药因安全性问题在海外“翻车”，遭欧美市场退市，是此次监管机构不予批准的主要原因。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-10-14/doc-inftvrrq4485805.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-14/doc-inftvrrq4485805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FXR","BK0239","688505","BK4081","EMA","BK4201","EC","PBC"],"gpt_icon":0},{"id":"2574432962","title":"Tharimmune, Inc.盤中異動 早盤急速拉升5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574432962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574432962?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 22:39","pubTimestamp":1760107161,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日22时39分，Tharimmune, Inc.股票出现异动，股价大幅上涨5.38%。Tharimmune, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Gyre Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Q32 Bio Inc.涨幅较大，Aditxt, Inc.、Cdt Equity Inc.、Intensity Therapeutics, Inc.较为活跃，换手率分别为321.98%、70.15%、49.71%，振幅较大的相关个股有Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 、Briacell Therapeutics Corp C/Wts 26/02/2026、知临集团，振幅分别为39.68%、33.20%、29.54%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，正在开发一系列用于治疗罕见免疫疾病、炎症疾病和肿瘤疾病的治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101022392194c204ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101022392194c204ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","THAR","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}